This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Value Stocks to Buy for November 13th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 13th
Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small Caps Win in September: 5 Best ETFs & Stocks
by Sweta Killa
We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.
Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.
Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Lexicon (LXRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -31.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
by Zacks Equity Research
FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
by Zacks Equity Research
Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 42.86% and 24.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Lexicon Pharmaceuticals (LXRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Lexicon, Medtronic and NetApp
by Zacks Equity Research
Zacks.com featured highlights include: Lexicon, Medtronic and NetApp
3 Stocks That Flaunt Solid Earnings Acceleration
by Tirthankar Chakraborty
Studies show that majority of successful stocks see acceleration in earnings before a positive stock price movement.
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and -48.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?